130 related articles for article (PubMed ID: 25735511)
1. Investigation of Paclitaxel Resistant R306C Mutation in β-Tubulin—A Computational Approach.
Verma K; Ramanathan K
J Cell Biochem; 2015 Jul; 116(7):1318-24. PubMed ID: 25735511
[TBL] [Abstract][Full Text] [Related]
2. Exploring the impact of F270V mutation in the β-tubulin (Bos Taurus) structure and its function: a computational perspective.
Verma K; Ramanathan K
Biotechnol Lett; 2015 May; 37(5):1003-11. PubMed ID: 25631779
[TBL] [Abstract][Full Text] [Related]
3. Molecular dynamics simulation and free energy landscape methods in probing L215H, L217R and L225M βI-tubulin mutations causing paclitaxel resistance in cancer cells.
Tripathi S; Srivastava G; Sharma A
Biochem Biophys Res Commun; 2016 Aug; 476(4):273-279. PubMed ID: 27233604
[TBL] [Abstract][Full Text] [Related]
4. Human mutations that confer paclitaxel resistance.
Yin S; Bhattacharya R; Cabral F
Mol Cancer Ther; 2010 Feb; 9(2):327-35. PubMed ID: 20103599
[TBL] [Abstract][Full Text] [Related]
5. The betaI/betaIII-tubulin isoforms and their complexes with antimitotic agents. Docking and molecular dynamics studies.
Magnani M; Ortuso F; Soro S; Alcaro S; Tramontano A; Botta M
FEBS J; 2006 Jul; 273(14):3301-10. PubMed ID: 16803461
[TBL] [Abstract][Full Text] [Related]
6. Structural insight into the mechanism of epothilone A bound to beta-tubulin and its mutants at Arg282Gln and Thr274Ile.
Shi G; Wang Y; Jin Y; Chi S; Shi Q; Ge M; Wang S; Zhang X; Xu S
J Biomol Struct Dyn; 2012; 30(5):559-73. PubMed ID: 22731768
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the effect of the chiral centers of Taxol on binding to β-tubulin: A docking and molecular dynamics simulation study.
Ghadari R; Alavi FS; Zahedi M
Comput Biol Chem; 2015 Jun; 56():33-40. PubMed ID: 25854803
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules.
Hari M; Loganzo F; Annable T; Tan X; Musto S; Morilla DB; Nettles JH; Snyder JP; Greenberger LM
Mol Cancer Ther; 2006 Feb; 5(2):270-8. PubMed ID: 16505100
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis for benzimidazole resistance from a novel β-tubulin binding site model.
Aguayo-Ortiz R; Méndez-Lucio O; Romo-Mancillas A; Castillo R; Yépez-Mulia L; Medina-Franco JL; Hernández-Campos A
J Mol Graph Model; 2013 Sep; 45():26-37. PubMed ID: 23995453
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer.
Giannakakou P; Poy G; Zhan Z; Knutsen T; Blagosklonny MV; Fojo T
Oncogene; 2000 Jun; 19(27):3078-85. PubMed ID: 10871860
[TBL] [Abstract][Full Text] [Related]
11. Wild-type class I beta-tubulin sensitizes Taxol-resistant breast adenocarcinoma cells harboring a beta-tubulin mutation.
Wiesen KM; Xia S; Yang CP; Horwitz SB
Cancer Lett; 2007 Nov; 257(2):227-35. PubMed ID: 17869412
[TBL] [Abstract][Full Text] [Related]
12. Molecular dynamics simulation and density functional theory studies on the active pocket for the binding of paclitaxel to tubulin.
Xu S; Chi S; Jin Y; Shi Q; Ge M; Wang S; Zhang X
J Mol Model; 2012 Jan; 18(1):377-91. PubMed ID: 21537957
[TBL] [Abstract][Full Text] [Related]
13. Structural investigations into the binding mode of novel neolignans Cmp10 and Cmp19 microtubule stabilizers by in silico molecular docking, molecular dynamics, and binding free energy calculations.
Tripathi S; Kumar A; Kumar BS; Negi AS; Sharma A
J Biomol Struct Dyn; 2016 Jun; 34(6):1232-40. PubMed ID: 26212016
[TBL] [Abstract][Full Text] [Related]
14. Exploring β-Tubulin Inhibitors from Plant Origin using Computational Approach.
Verma K; Kannan K; V S; R S; V K; K R
Phytochem Anal; 2017 May; 28(3):230-241. PubMed ID: 28008675
[TBL] [Abstract][Full Text] [Related]
15. Mutations at leucine 215 of beta-tubulin affect paclitaxel sensitivity by two distinct mechanisms.
Wang Y; Yin S; Blade K; Cooper G; Menick DR; Cabral F
Biochemistry; 2006 Jan; 45(1):185-94. PubMed ID: 16388594
[TBL] [Abstract][Full Text] [Related]
16. Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.
Tommasi S; Mangia A; Lacalamita R; Bellizzi A; Fedele V; Chiriatti A; Thomssen C; Kendzierski N; Latorre A; Lorusso V; Schittulli F; Zito F; Kavallaris M; Paradiso A
Int J Cancer; 2007 May; 120(10):2078-85. PubMed ID: 17285590
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel resistance in cells with reduced beta-tubulin.
Wang Y; Cabral F
Biochim Biophys Acta; 2005 Jun; 1744(2):245-55. PubMed ID: 15950754
[TBL] [Abstract][Full Text] [Related]
18. Intra-allelic suppression of a mutation that stabilizes microtubules and confers resistance to colcemid.
Wang Y; Veeraraghavan S; Cabral F
Biochemistry; 2004 Jul; 43(28):8965-73. PubMed ID: 15248754
[TBL] [Abstract][Full Text] [Related]
19. Increased levels of tyrosinated alpha-, beta(III)-, and beta(IV)-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells.
Banerjee A
Biochem Biophys Res Commun; 2002 Apr; 293(1):598-601. PubMed ID: 12054644
[TBL] [Abstract][Full Text] [Related]
20. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol).
Dumontet C; Duran GE; Steger KA; Beketic-Oreskovic L; Sikic BI
Cancer Res; 1996 Mar; 56(5):1091-7. PubMed ID: 8640766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
